Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thoracic radiotherapy added to durvalumab plus carboplatin/etoposide for extensive-stage small-cell lung cancer
NL-OMON53938Phase 3Not yet recruiting
- Sponsor
- University of Science & Technology
- Start
- Jan 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by University of Science & Technology. Primary endpoint: 1-year overall survival. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
durvalumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON53938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53938.